Department of Surgery, University of Minnesota School of Medicine, Minneapolis, MN; Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, MN.
Department of Surgery, University of Minnesota School of Medicine, Minneapolis, MN.
J Am Coll Surg. 2014 Apr;218(4):530-43. doi: 10.1016/j.jamcollsurg.2013.12.037. Epub 2014 Jan 10.
Chronic pancreatitis is a debilitating disease resulting from many causes. The subset with hereditary/genetic pancreatitis (HGP) not only has chronic pain, but also an increased risk for pancreatic cancer. Long-term outcomes of total pancreatectomy (TP) and islet autogeneic transplantation (IAT) for chronic pancreatitis due to HGP are not clear.
We reviewed a prospectively maintained database of 484 TP-IATs from 1977 to 2012 at a single center. The outcomes (eg, pain relief, narcotic use, β-cell function, health-related quality of life measures) of patients who received TP-IAT for HGP (protease trypsin 1, n = 38; serine protease inhibitor Kazal type 1, n = 9; cystic fibrosis transmembrane conductance regulator, n = 14; and familial, n = 19) were evaluated and compared with those with non-hereditary/nongenetic causes.
All 80 patients with HGP were narcotic dependent and failed endoscopic management or direct pancreatic surgery. Post TP-IAT, 90% of the patients were pancreatitis pain free with sustained pain relief; >65% had partial or full β-cell function. Compared with nonhereditary causes, HGP patients were younger (22 years old vs 38 years old; p ≤ 0.001), had pancreatitis pain of longer duration (11.6 ± 1.1 years vs 9.0 ± 0.4 years; p = 0.016), had a higher pancreas fibrosis score (7 ± 0.2 vs 4.8 ± 0.1; p ≤ 0.001), and trended toward lower islet yield (3,435 ± 361 islet cell equivalent vs 3,850 ± 128 islet cell equivalent; p = 0.28). Using multivariate logistic regression, patients with non-HGP causes (p = 0.019); lower severity of pancreas fibrosis (p < 0.001); shorter duration of years with pancreatitis (p = 0.008); and higher transplant islet cell equivalent per kilogram body weight (p ≤ 0.001) were more likely to achieve insulin independence (p < 0.001). There was a significant improvement in health-related quality of life from baseline by RAND 36-Item Short Form Health Survey and in physical and mental component health-related quality of life scores (p < 0.001). None of the patients in the entire cohort had cancer of pancreatic origin in the liver or elsewhere develop during 2,936 person-years of follow-up.
Total pancreatectomy and IAT in patients with chronic pancreatitis due to HGP cause provide long-term pain relief (90%) and preservation of β-cell function. Patients with chronic painful pancreatitis due to HGP with a high lifetime risk of pancreatic cancer should be considered earlier for TP-IAT before pancreatic inflammation results in a higher degree of pancreatic fibrosis and islet cell function loss.
慢性胰腺炎是一种由多种原因引起的使人虚弱的疾病。遗传性/遗传胰腺炎(HGP)亚组不仅有慢性疼痛,而且还存在胰腺癌风险增加。由于 HGP 导致的全胰切除术(TP)和胰岛自体移植(IAT)的长期结果尚不清楚。
我们在一个中心回顾了 1977 年至 2012 年期间前瞻性维护的 484 例 TP-IAT 数据库。评估了因 HGP(蛋白酶胰蛋白酶 1,n = 38;丝氨酸蛋白酶抑制剂 Kazal 1 型,n = 9;囊性纤维化跨膜电导调节剂,n = 14;家族性,n = 19)接受 TP-IAT 的患者的结局(例如,疼痛缓解,使用麻醉性镇痛药,β细胞功能,健康相关生活质量测量),并将其与非遗传性/非遗传性原因的患者进行了比较。
所有 80 例 HGP 患者均依赖麻醉性镇痛药,且内镜治疗或直接胰腺手术均失败。TP-IAT 后,90%的患者胰腺炎疼痛缓解,且疼痛缓解持续;> 65%的患者具有部分或完全β细胞功能。与非遗传性病因相比,HGP 患者更年轻(22 岁比 38 岁;p ≤ 0.001),胰腺炎疼痛持续时间更长(11.6 ± 1.1 年比 9.0 ± 0.4 年;p = 0.016),胰腺纤维化评分更高(7 ± 0.2 比 4.8 ± 0.1;p ≤ 0.001),胰岛产率趋势较低(3435 ± 361 胰岛细胞当量比 3850 ± 128 胰岛细胞当量;p = 0.28)。使用多变量逻辑回归,非 HGP 病因(p = 0.019);胰腺纤维化程度较低(p <0.001);胰腺炎病史较短(p = 0.008);和更高的胰岛细胞移植当量每千克体重(p ≤ 0.001)更有可能实现胰岛素独立性(p <0.001)。RAND 36-Item 短期健康调查和身体和精神健康相关生活质量评分的健康相关生活质量均有显著改善(p <0.001)。在整个队列中,没有患者在 2936 人年的随访中发生肝脏或其他部位起源于胰腺的癌症。
HGP 引起的慢性胰腺炎患者的全胰切除术和 IAT 可长期缓解疼痛(90%)并维持β细胞功能。具有高终生胰腺癌风险的 HGP 引起的慢性疼痛性胰腺炎患者,在胰腺炎症导致更高程度的胰腺纤维化和胰岛细胞功能丧失之前,应更早考虑进行 TP-IAT。